CA3193940A1 - Topical ophthalmological compositions - Google Patents

Topical ophthalmological compositions

Info

Publication number
CA3193940A1
CA3193940A1 CA3193940A CA3193940A CA3193940A1 CA 3193940 A1 CA3193940 A1 CA 3193940A1 CA 3193940 A CA3193940 A CA 3193940A CA 3193940 A CA3193940 A CA 3193940A CA 3193940 A1 CA3193940 A1 CA 3193940A1
Authority
CA
Canada
Prior art keywords
atropine
topical ophthalmological
ophthalmological composition
topical
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3193940A
Other languages
English (en)
French (fr)
Inventor
Jinsong Ni
Rong Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADS Therapeutics LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3193940A1 publication Critical patent/CA3193940A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3193940A 2020-10-08 2021-10-08 Topical ophthalmological compositions Pending CA3193940A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063089263P 2020-10-08 2020-10-08
US63/089,263 2020-10-08
PCT/US2021/054221 WO2022076852A1 (en) 2020-10-08 2021-10-08 Topical ophthalmological compositions

Publications (1)

Publication Number Publication Date
CA3193940A1 true CA3193940A1 (en) 2022-04-14

Family

ID=78818588

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3193940A Pending CA3193940A1 (en) 2020-10-08 2021-10-08 Topical ophthalmological compositions

Country Status (11)

Country Link
US (2) US11191751B1 (https=)
EP (2) EP4225284B1 (https=)
JP (1) JP2023544853A (https=)
KR (1) KR20230084190A (https=)
CN (1) CN116390714A (https=)
AU (1) AU2021359003A1 (https=)
BR (1) BR112023006371A2 (https=)
CA (1) CA3193940A1 (https=)
ES (1) ES3063371T3 (https=)
MX (1) MX2023004065A (https=)
WO (1) WO2022076852A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251875B2 (en) 2017-05-11 2019-04-09 Nevakar Inc. Atropine pharmaceutical compositions
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
MX2023009091A (es) 2021-02-03 2023-08-09 Ads Therapeutics Llc Composiciones oftalmologicas topicas.
KR20240136369A (ko) * 2022-01-21 2024-09-13 에이디에스 테라퓨틱스 엘엘씨 8-메틸-8-아자비사이클로[3.2.1] 옥탄-3-일의 에스테르 3-하이드록시-2-페닐프로파노에이트
JP2025541009A (ja) 2022-12-23 2025-12-17 ノバリック ゲーエムベーハー ヒヨスチアミンを含む半フッ化アルカン組成物
CN117982412B (zh) * 2024-02-04 2024-09-17 济川(上海)医学科技有限公司 一种醋克利定眼用组合物及其药物制剂和用途
WO2025259674A1 (en) * 2024-06-11 2025-12-18 Ads Therapeutics Llc Compositions and methods for delivery of pharmaceutical actives
WO2025264886A1 (en) * 2024-06-19 2025-12-26 Btv Holding, Llc Ophthalmic preparations and methods of use
WO2026011139A1 (en) * 2024-07-05 2026-01-08 Ads Therapeutics Llc Transient receptor potential melastatin 8 agonist-containing ocular conditions and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070254914A1 (en) * 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
EP2335735A1 (en) * 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
CN102526051A (zh) * 2012-03-09 2012-07-04 哈尔滨医科大学 一种治疗真菌性角膜炎的眼药膏
CN113679699B (zh) * 2012-09-12 2022-10-28 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
US9421199B2 (en) * 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US11510931B2 (en) * 2016-09-28 2022-11-29 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
AU2017333420A1 (en) * 2016-09-28 2019-04-04 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
BR112019012568A2 (pt) * 2016-12-22 2019-11-26 Novaliq Gmbh composições compreendendo tacrolimus para o tratamento de doenças intraoculares inflamatórias
WO2019068763A1 (en) * 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
TW201932104A (zh) * 2017-11-03 2019-08-16 澳大利亞商布萊恩荷登視覺協會 用於控制及/或降低近視進展之醫藥組合物
SG11202102820VA (en) * 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
WO2020152046A1 (en) * 2019-01-21 2020-07-30 Novaliq Gmbh Pharmaceutical composition for the treatment of ocular neovascularisation
CA3128224A1 (en) * 2019-02-01 2020-08-06 Aerie Pharmaceuticals, Inc. Compounds, compositions and methods for treatment of myopia
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
MX2023009091A (es) * 2021-02-03 2023-08-09 Ads Therapeutics Llc Composiciones oftalmologicas topicas.

Also Published As

Publication number Publication date
CN116390714A (zh) 2023-07-04
US20230355594A1 (en) 2023-11-09
EP4706766A2 (en) 2026-03-11
EP4225284B1 (en) 2025-11-26
WO2022076852A1 (en) 2022-04-14
AU2021359003A1 (en) 2023-05-04
ES3063371T3 (en) 2026-04-16
US11191751B1 (en) 2021-12-07
EP4225284C0 (en) 2025-11-26
KR20230084190A (ko) 2023-06-12
BR112023006371A2 (pt) 2023-05-09
JP2023544853A (ja) 2023-10-25
EP4225284A1 (en) 2023-08-16
MX2023004065A (es) 2023-05-03
AU2021359003A9 (en) 2024-06-13
EP4225284A4 (en) 2024-10-09

Similar Documents

Publication Publication Date Title
US11191751B1 (en) Topical ophthalmological atropine free base compositions
US12485177B2 (en) Topical ophthalmological compositions
WO2020152046A1 (en) Pharmaceutical composition for the treatment of ocular neovascularisation
CN110237233B (zh) 一种含有环孢素的眼用药物组合物、其制备方法及用途
HU203046B (en) Process for producing ophtalmological compositions containing cyclosporin
Okka et al. Effects of latrunculin B on outflow facility, intraocular pressure, corneal thickness, and miotic and accommodative responses to pilocarpine in monkeys
Vale et al. Drugs and the Eye: Sponsored by the British Optical Association
McCLANAHAN et al. Ocular manifestations of chronic phenothiazine derivative administration
CN110833526B (zh) 一种防治青少年近视的眼用制剂及其制备方法
US20030119832A1 (en) Treatment of ocular disorders
US20260124305A1 (en) Topical ophthalmological compositions
EP0205606B1 (en) Pharmaceutical compositions and their use as mydriatics
CN115957216A (zh) 眼用制剂及其制备方法和用途
HK40086649A (zh) 局部眼科组合物
CN120093684A (zh) 局部眼科组合物
HK40126394A (zh) 一种α-肾上腺素受体激动剂眼用组合物及其用途
WO2025163485A1 (en) Ophthalmic pharmaceutical composition
CN115702879A (zh) 一种硫酸阿托品的滴眼液
CN118806757A (zh) 眼用制剂及其制备方法和用途
Anand et al. Ocular toxicity of organochlorinated pesticides in rabbits
EA041767B1 (ru) Применение тиотропия для изготовления средства для предупреждения миопии, лечения миопии и/или предупреждения прогрессирования миопии

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240827

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240827

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240827

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250220

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250220

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250220

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250820

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250820

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250820

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250903

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - SMALL

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251006

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251006

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251031

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20251031

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251031

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251031

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251104